Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04988386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Study acronym: AG10
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Study description expanded, about 48 words Site details revised at 7 of 72 sitesv9 Show 1 more changeShow less
    • Site details revised at 7 of 72 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Enrolling by Invitation to Active, Not Recruiting Enrollment target: estimated 545 to confirmed 389 · Study sites revised (72)v8 Show 2 more changesShow less
    • Enrollment target: estimated 545 to confirmed 389
    • Study sites revised (72)

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 105 to 72v7
  5. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date changed from estimate of Oct 23, 2021 to Oct 27, 2021 · Site contacts updated at 5 of 105 sitesv6 Show 2 more changesShow less
    • Start date changed from estimate of Oct 23, 2021 to Oct 27, 2021
    • Site contacts updated at 5 of 105 sites
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Study sites: 110 to 105v4
  3. Re-verified, no change to tracked fieldsv3
  4. Secondary endpoints: details revised at 1 of 4 entriesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Trial Details
NCT Number NCT04988386
Lead Sponsor Eidos Therapeutics, a BridgeBio company
Conditions Amyloid Cardiomyopathy, Transthyretin-Related
Enrollment 389 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov